The B72.3 mAb, generated by mice immunization with human breast carcinoma cells, was the first anti-STn mAb described and has been widely used in both tissue-based and serological assays, as well as in preclinical studies (49–53).In this work, we address this research gap by performing a comprehensive study on the expression patterns of STn in normal, premalignant, and malignant lesions of the pancreas using the B72.3 mAb. Here, EEF1A2 is linked to breast carcinoma.